Dermatology | Phase I Developments | CANADA

InMed Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Lead Product(s): Cannabinol

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 01, 2020

Details:

Study 755-101-HV is a randomized Phase 1 trial, examining the safety and tolerability of two strengths of INM-755 cream in 22 healthy adult volunteers over a 14-day treatment.

InMed Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial

Lead Product(s): Cannabinol

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 24, 2020

Details:

755-102-HV will evaluate the safety and tolerability of INM-755 cream applied daily on epidermal wounds in healthy volunteers.

InMed Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

InMed Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN

Lead Product(s): Cannabinol

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 10, 2020

Details:

With enrollment completed, treatment is expected to conclude towards the end of March and results are anticipated to be announced in the second half of calendar 2020.

InMed Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

AFSSI Connexions 2020

Participation Not Confirmed

Update your events

InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials

Lead Product(s): Cannabinol

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 20, 2020

Details:

InMed Pharmaceuticals, revealed the rare cannabinoid cannabinol as the active pharmaceutical ingredient in its two product candidates under development: INM-755 for epidermolysis bullosa and INM-088.

Find

Find Dermatology Drugs in Phase I Clinical Development in CANADA

Canada

Product Type

Companies

InMed Pharmaceuticals

InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

InMed Pharmaceuticals

InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial

InMed Pharmaceuticals

InMed Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN

InMed Pharmaceuticals

InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials